Cargando…

Canakinumab treatment in patients with active recurrent or chronic TNF-receptor associated syndrome (TRAPS): Efficacy and safety results from a proof of concept study

Detalles Bibliográficos
Autores principales:	Lachmann, H, Cattalini, M, Obici, L, Barcellona, R, Speziale, A, Joubert, Y, Junge, G, Gattorno, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4597075/ http://dx.doi.org/10.1186/1546-0096-13-S1-O59

Ejemplares similares

Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
por: Gattorno, Marco, et al.
Publicado: (2017)

Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study
por: Aróstegui, JI, et al.
Publicado: (2015)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Gene expression profiling in understanding the molecular pathogenesis of and response to canakinumab therapy in traps
por: Gattorno, M, et al.
Publicado: (2014)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome
por: Torene, Rebecca, et al.
Publicado: (2017)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study
por: Krause, K, et al.
Publicado: (2015)

12.3 Long-term follow up of patients with CINCA syndrome: efficacy and tolerability of Anakinra treatment
por: Paloni, G, et al.
Publicado: (2008)

Proof-of-concept in vivo evaluation of targeted therapeutics: lessons from immunoliposomes
por: Benz, CC
Publicado: (2003)

Is a cure for HIV feasible? A proof-of-concept in humanized mice
por: Speck, Roberto
Publicado: (2013)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Rapid and sustained effect of anti-TNF treatment in patients with ADA2 deficiency
por: Caorsi, R, et al.
Publicado: (2015)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

MR-Augmented Cardiopulmonary Exercise Testing- a proof of concept in Sickle Cell Disease (SCD)
por: Ako, Emmanuel O, et al.
Publicado: (2016)

O025 Smart polymer implants as an emerging technology for treating airway collapse in obstructive sleep apnea: proof of concept
por: Sideris, A, et al.
Publicado: (2021)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

First case of somatic mosaicism in TRAPS caused by a novel 24 nucleotides deletion in the TNFRSF1A gene
por: Rowczenio, D, et al.
Publicado: (2015)

PW02-008 - TRAPS in the real world: an international registry
por: Lachmann, HJ, et al.
Publicado: (2013)

Genes responding to Canakinumab therapy in SJIA are -inversely - disregulated in adult onset Still's disease
por: Brachat, A, et al.
Publicado: (2015)

O027 A randomised dose finding study of combination dronabinol and acetazolamide for the treatment of obstructive sleep apnoea: A proof of concept study
por: Walsh, J, et al.
Publicado: (2022)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

A Next Generation Sequencing approach to the mutational screening of patients affected with systemic autoinflammatory disorders: diagnosis improvement and interpretation of complex clinical phenotypes
por: Rusmini, M, et al.
Publicado: (2015)

Volumetric MR-guided high-intensity focused ultrasound with direct skin cooling for the treatment of symptomatic uterine fibroids: proof of concept study
por: Ikink, Marlijne, et al.
Publicado: (2015)

12.4 ACZ885 (canakinumab), a new IL-1 beta blocking monoclonal antibody provides long-lasting remission in children with cryopyrin associated periodic syndrome (CAPS)
por: Kümmerle-Deschner, J, et al.
Publicado: (2008)

The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry
por: Lachmann, H J, et al.
Publicado: (2014)

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation
por: Cremer, Paul C, et al.
Publicado: (2021)

Reverse signalling of membrane TNF in human natural killer cells: a comparison of the effect of certolizumab pegol and other anti-TNF agents
por: Fossati, Gianluca, et al.
Publicado: (2011)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Antimalarial activity of ulein and proof of its action on the Plasmodium falciparum digestive vacuole
por: de Oliveira, Alaíde Braga, et al.
Publicado: (2010)

New mechanisms of action and signaling by TNF-α
por: Ivashkiv, Lionel B
Publicado: (2012)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Clinical response to the canakinumab in crohn’s disease related artrhritis
por: Gündüz, Zübeyde, et al.
Publicado: (2014)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

Development of a SMCs model from HGPS-iPS and proofs of principle
por: Ferreira, Lino
Publicado: (2015)

Diflunisal in late-onset FAP patients with moderate to severe neuropathy
por: Obici, Laura, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p8d0bem6tmfma9j0nopv02n3c4